MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 17:02:37 01/07/2024 BST | ||
| 5.605 EUR | +1.45% |
|
| 1 month | +24.72% | ||
| 3 months | +38.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 5.605 | +1.45% |
| 28/06/24 | 5.525 | +1.47% |
| 27/06/24 | 5.445 | -1.98% |
| 26/06/24 | 5.555 | -3.98% |
| 25/06/24 | 5.785 | +9.25% |
Real-time Euronext Paris
Last update July 01, 2024 at 05:02 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| KL3MB | |
| ISIN | NLBNPNL2JEC9 |
| Date issued | 17/10/2023 |
| Strike | 594.6 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.875 € |
|---|---|
| Lowest since issue | 0.98 € |
| Spread | 0.01 € |
| Spread % | 0.18% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- KL3MB Certificat
